{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:18:26Z","timestamp":1759011506833},"reference-count":35,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Anthrax vaccine adsorbed (AVA; BioThrax), the current FDA-licensed human anthrax vaccine, contains various amounts of the three anthrax toxin components, protective antigen (PA), lethal factor (LF), and edema factor (EF). While antibody to PA is sufficient to mediate protection against anthrax in animal models, it is not known if antibodies to LF or EF contribute to protection in humans. Toxin-neutralizing activity was evaluated in sera from AVA-vaccinated volunteers, all of whom had antibody responses to LF and EF, as well as PA. The contribution of antibodies to LF and EF was assessed using mouse macrophage J774A.1 cells by examining neutralization of LF-induced lysis using alamarBlue reduction and neutralization of EF-induced cyclic AMP increases by enzyme-linked immunosorbent assay. Antibody responses to LF and EF were low compared to those to PA, and the amount of LF or EF in the assay could exceed the amount of antibodies to LF or EF. Higher titers were seen for most individuals when the LF or EF concentration was limiting compared to when LF or EF was in excess, initially suggesting that antibody to LF or EF augmented protection. However, depletion of LF and EF antibodies in sera did not result in a significant decrease in toxin neutralization. Overall, this study suggests that AVA-induced LF and EF antibodies do not significantly contribute to anthrax toxin neutralization in humans and that antibodies to PA are sufficient to neutralize toxin activity.<\/jats:p>","DOI":"10.1128\/cvi.00321-07","type":"journal-article","created":{"date-parts":[[2007,11,22]],"date-time":"2007-11-22T02:06:34Z","timestamp":1195697194000},"page":"71-75","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Neutralizing Activity of Vaccine-Induced Antibodies to Two<i>Bacillus anthracis<\/i>Toxin Components, Lethal Factor and Edema Factor"],"prefix":"10.1128","volume":"15","author":[{"given":"Sarah C.","family":"Taft","sequence":"first","affiliation":[{"name":"Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, Ohio 45267-0524"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison A.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, Ohio 45267-0524"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1073\/pnas.86.7.2209","volume":"86","year":"1989","unstructured":"Blaustein, R. O., T. M. Koehler, R. J. Collier, and A. Finkelstein. 1989. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. USA86:2209-2213.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","volume":"52","year":"1962","unstructured":"Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health52:632-645.","journal-title":"Am. J. Public Health"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","volume":"57","year":"2005","unstructured":"Brey, R. N. 2005. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev.57:1266-1292.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","volume":"19","year":"2003","unstructured":"Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol.19:45-70.","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","volume":"280","year":"1998","unstructured":"Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science280:734-737.","journal-title":"Science"},{"key":"e_1_3_2_7_2","first-page":"217","volume":"20","year":"2002","unstructured":"Geier, D. A., and M. R. Geier. 2002. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol.20:217-220.","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_8_2","first-page":"762","volume":"51","year":"2004","unstructured":"Geier, M. R., and D. A. Geier. 2004. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology51:762-767.","journal-title":"Hepatogastroenterology"},{"key":"e_1_3_2_9_2","first-page":"74","volume":"167","year":"2002","unstructured":"Greidanus, T. G., and B. A. Honl. 2002. Delayed-type hypersensitivity reaction to anthrax vaccine. Mil. Med.167:74-75.","journal-title":"Mil. Med."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1091\/mbc.3.11.1269","volume":"3","year":"1992","unstructured":"Hanna, P. C., S. Kochi, and R. J. Collier. 1992. Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol. Biol. Cell3:1269-1277.","journal-title":"Mol. Biol. Cell"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.2.208-213.2006"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.52.2.454-458.1986"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF00152686","volume":"4","year":"1988","unstructured":"Ivins, B. E., and S. L. Welkos. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol.4:12-19.","journal-title":"Eur. J. Epidemiol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","volume":"79","year":"1982","unstructured":"Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA79:3162-3616.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI0216204","volume":"110","year":"2002","unstructured":"Leppla, S. H., J. B. Robbins, R. Schneerson, and J. Shiloach. 2002. Development of an improved vaccine for anthrax. J. Clin. Investig.110:141-144.","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00063030-200519040-00003","volume":"19","year":"2005","unstructured":"Little, S. F. 2005. Anthrax vaccines: a development update. BioDrugs19:233-245.","journal-title":"BioDrugs"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.12.5171-5175.1997"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.52.2.509-512.1986"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.7.1807-1813.1988"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.96.4.727","volume":"96","year":"1966","unstructured":"Mahlandt, B. G., F. Klein, R. E. Lincoln, B. W. Haines, W. I. Jones, Jr., and R. H. Friedman. 1966. Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin. J. Immunol.96:727-733.","journal-title":"J. Immunol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.171.2.722-730.1989"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0736-4679(03)00201-4","volume":"25","year":"2003","unstructured":"Muniz, A. E. 2003. Lymphocytic vasculitis associated with the anthrax vaccine: case report and review of anthrax vaccination. J. Emerg. Med.25:271-276.","journal-title":"J. Emerg. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.4.1369-1372.1995"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.68.4.617-629.2004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","volume":"20","year":"2001","unstructured":"Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine20:972-978.","journal-title":"Vaccine"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.11.4.330-334.1963"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.vaccine.2005.08.065","volume":"24","year":"2006","unstructured":"Quesnel-Hellmann, A., A. Cleret, D. R. Vidal, and J. N. Tournier. 2006. Evidence for adjuvanticity of anthrax edema toxin. Vaccine24:699-702.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s00018-006-6312-3","volume":"63","year":"2006","unstructured":"Scorpio, A., T. E. Blank, W. A. Day, and D. J. Chabot. 2006. Anthrax vaccines: Pasteur to the present. Cell. Mol. Life Sci.63:2237-2248.","journal-title":"Cell. Mol. Life Sci."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"11099","DOI":"10.1016\/S0021-9258(18)60433-8","volume":"264","year":"1989","unstructured":"Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander. 1989. Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J. Biol. Chem.264:11099-11102.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1099\/00221287-31-2-329","volume":"31","year":"1963","unstructured":"Stanley, J. L., and H. Smith. 1963. The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity. J. Gen. Microbiol.31:329-337.","journal-title":"J. Gen. Microbiol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/CLT-100102885","volume":"39","year":"2001","unstructured":"Swanson-Biearman, B., and E. P. Krenzelok. 2001. Delayed life-threatening reaction to anthrax vaccine. J. Toxicol. Clin. Toxicol.39:81-84.","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0264-410X(91)90237-Z","volume":"9","year":"1991","unstructured":"Turnbull, P. C. 1991. Anthrax vaccines: past, present and future. Vaccine9:533-539.","journal-title":"Vaccine"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.52.2.356-363.1986"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1081-1206(10)61379-8","volume":"97","year":"2006","unstructured":"Vasudev, M., and M. C. Zacharisen. 2006. New-onset rheumatoid arthritis after anthrax vaccination. Ann. Allergy Asthma Immunol.97:110-112.","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"15737","DOI":"10.1021\/bi981436i","volume":"37","year":"1998","unstructured":"Wesche, J., J. L. Elliott, P. O. Falnes, S. Olsnes, and R. J. Collier. 1998. Characterization of membrane translocation by anthrax protective antigen. Biochemistry37:15737-15746.","journal-title":"Biochemistry"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1016\/j.vaccine.2004.04.036","volume":"22","year":"2004","unstructured":"Whiting, G. C., S. Rijpkema, T. Adams, and M. J. Corbel. 2004. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine22:4245-4251.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00321-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00321-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T21:55:34Z","timestamp":1684101334000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00321-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1128\/CVI.00321-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00321-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"2007-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-11-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}